key: cord-0919800-rdilt94j
authors: Mehmood, Qasim; Irfan, Muhammad; Ogunkola, Isaac Olushola; Jaguga, Florence; Ullah, Irfan
title: Rift Valley Fever and COVID-19 outbreak in Kenya: a double whammy
date: 2021-06-09
journal: Ethics Med Public Health
DOI: 10.1016/j.jemep.2021.100685
sha: a9f73b7d7d71ae2f600f6bd5077c79d8c6694da0
doc_id: 919800
cord_uid: rdilt94j

nan

Rift Valley Fever (RVF), a vector-borne infection caused by Phlebovirus [1] , is an emerging public health concern in Kenya [2] . Rift Valley Fever virus, which is a single-stranded RNA virus, was first detected in sheep in the Rift Valley province of Kenya in 1931 [3] . Since then, frequent outbreaks of this virus has been reported in Kenya in 1998 Kenya in , 2006 Kenya in -2007 Kenya in , 2014 Kenya in , and 2018 . Rift Valley Fever outbreak between the year 2006 and 2007 steered to more than 340 confirmed cases, 90 deaths, and economic losses of over US$32 million [1] . RVF in humans varies from mild influenza-like symptoms to more complicated conditions like retinitis, viral encephalitis, hemorrhagic fever, kidney damage, jaundice, and other signs of liver dysfunction.

Human transmission occurs via a bite from an infected mosquito, contact with infected blood, or body fluids. It can also be transmitted through contact with the contaminated animal placenta or blood during animal slaughter, and consumption of raw meat or contaminated milk from infected animals [5] .

Studies has shown that livestock like sheep, cattle, and camels serve as significant amplifiers of the RVF virus [6] . Live attenuated vaccinate against RVF for both animals and humans has recently been developed. People at high risk of getting RVF infection like herders, farmers, butchers, scientists, and animal health workers should be encouraged to receive the vaccine on priority basis [7] .

Kenya provides favorable conditions for rapid multiplication of mosquito vector which has led to another outbreak of RVF in 2020. Since the RVF outbreak began in Eastern Kenya in November 2020 amidst the COVID-19 pandemic, many cases of suspected RVF have been detected in Isiolo and Mandera [8] . High numbers of human cases infected with RVF have been documented, resulting in serious healthcare challenges [5] . As reported on 4 February 2021, there were 32 confirmed human cases of RVF and 11 human deaths, with a fatality ratio of 34.4% [9] . The COVID-19 pandemic has imposed additional healthcare challenges in countries with overlapping epidemics like Kenya [10] .

In March 2020, COVID-19 was declared as a global pandemic by WHO [11] . The first human [12] , India [11] , and Africa [13] , as people in their homes maintained close contact with breeding sites of mosquitos. People focusing on COVID-19 forgot to adopt preventive measures for other diseases. Health system is also exhausted dealing with COVID-19 pandemic which has led to various challenges for healthcare authorities [13] .

COVID-19 and Rift Valley fever may present similar clinical manifestations in the early stages resulting in a confused final diagnosis. Misdiagnosis presents as an emerging healthcare challenge leading to delay in suitable care and management of the patient [12] . COVID-19 patients require proper care and strict isolation to limit viral spread. If a patient with COVID-19 infection is misdiagnosed as having RVF, significant healthcare concerns may arise. The limited capacity of RVF differential diagnosis in health centers of Kenya has become worse during the pandemic. There is also a low suspicion index among healthcare workers of Kenya for RVF which can affect disease prognosis. Delayed detection of the virus could be associated with the low opportunities for early diagnosis and management [1] . COVID-19 pandemic also resulted in a lack of supplies required to limit RVF spread in Kenya. Furthermore, the prioritization of COVID-19 patients by healthcare professionals and laboratories in Kenya has also blunted the response to the RVF outbreak [4] .

Probable methods to control and prevent RVF outbreaks in Kenya are serosurveys and vaccination of the infected animals [14] . Routine vaccination in animals should be encouraged to prevent human infections [5] . However, mass vaccination programs against RVF infection are also a challenge amidst COVID-19 vaccination drives when herd immunity has yet to be achieved globally. Lack of adequate knowledge on cost-effectiveness and availability of RVF vaccines suggests further studies on these issues [14] . 

Epidemiological investigation of a Rift Valley fever outbreak in humans and livestock in Kenya

Zoonotic pathogens of dromedary camels in Kenya: a systematised review

Serological evidence of single and mixed infections of Rift Valley fever virus, Brucella spp. and Coxiella burnetii in dromedary camels in Kenya

Rift Valley fever -Kenya. WHO Emergency preparedness

The one health approach is necessary for the control of Rift Valley fever infections in Egypt: a comprehensive review

A Review of zoonotic pathogens of dromedary camels

Rift Valley fever vaccines: an overview of the safety and efficacy of the liveattenuated MP-12 vaccine candidate

Rift Valley Fever outbreak reported in Kenya

Rift Valley Fever in Eastern Kenya. Outbreak Observatory

Impact of concurrent epidemics of dengue, chikungunya, zika, and COVID-19. Revista da Sociedade Brasileira de

Covid-19 and dengue: Double punches for dengue-endemic countries in Asia

Chikungunya and COVID-19 in Brazil: the danger of overlapping crises

Access to primary healthcare during lockdown measures for COVID-19 in rural South Africa: a longitudinal cohort study

Epidemiology of brucellosis, Q Fever and Rift Valley Fever at the human and livestock interface in northern Côte d'Ivoire